---
document_datetime: 2025-12-29 12:21:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/celdoxome-pegylated-liposomal.html
document_name: celdoxome-pegylated-liposomal.html
version: success
processing_time: 0.1126027
conversion_datetime: 2025-12-30 02:19:20.606364
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Celdoxome pegylated liposomal

[RSS](/en/individual-human-medicine.xml/67595)

##### Lapsed

This medicine's authorisation has lapsed

doxorubicin hydrochloride Medicine Human Lapsed

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Celdoxome pegylated liposomal](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 22 September 2025 the marketing authorisation of Celdoxome pegylated liposomal (doxorubicin) ceased to be valid in the European Union (EU).

The cessation of validity is due to the fact that the marketing authorisation holder, Baxter Holding B.V., had not marketed Celdoxome pegylated liposomal in the EU since its initial marketing authorisation. In accordance with provisions of the sunset clause 1 , the marketing authorisation of the medicinal product lapsed as the product had not been marketed in any of the EU Member States within three years of its initial authorisation.

Baxter Holding B.V. confirmed that the product had not been marketed due to business reasons.

Celdoxome pegylated liposomal was granted marketing authorisation in the EU on 15 September 2022 for the treatment of breast cancer, ovarian cancer, multiple myeloma, AIDS related Kaposi's sarcoma.

The marketing authorisation was initially valid for a 5-year period.

Celdoxome pegylated liposomal is a hybrid medicine of Adriamycin. There are other medicines containing doxorubicin authorised and marketed in the EU.

1 Article 14(4) of Regulation (EC) No 726/2004 (\"sunset clause\")

Celdoxome pegylated liposomal : EPAR - Medicine Overview

Reference Number: EMA/695741/2022

English (EN) (131.43 KB - PDF)

**First published:** 31/01/2023

**Last updated:** 27/11/2025

[View](/en/documents/overview/celdoxome-pegylated-liposomal-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-178)

български (BG) (184.06 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/bg/documents/overview/celdoxome-pegylated-liposomal-epar-medicine-overview_bg.pdf)

español (ES) (153.18 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/es/documents/overview/celdoxome-pegylated-liposomal-epar-medicine-overview_es.pdf)

čeština (CS) (177.03 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/cs/documents/overview/celdoxome-pegylated-liposomal-epar-medicine-overview_cs.pdf)

dansk (DA) (152.91 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/da/documents/overview/celdoxome-pegylated-liposomal-epar-medicine-overview_da.pdf)

Deutsch (DE) (157.28 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/de/documents/overview/celdoxome-pegylated-liposomal-epar-medicine-overview_de.pdf)

eesti keel (ET) (141.02 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/et/documents/overview/celdoxome-pegylated-liposomal-epar-medicine-overview_et.pdf)

ελληνικά (EL) (185.4 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/el/documents/overview/celdoxome-pegylated-liposomal-epar-medicine-overview_el.pdf)

français (FR) (154.53 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/fr/documents/overview/celdoxome-pegylated-liposomal-epar-medicine-overview_fr.pdf)

hrvatski (HR) (175.85 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/hr/documents/overview/celdoxome-pegylated-liposomal-epar-medicine-overview_hr.pdf)

italiano (IT) (152.43 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/it/documents/overview/celdoxome-pegylated-liposomal-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (196.95 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/lv/documents/overview/celdoxome-pegylated-liposomal-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (177.29 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/lt/documents/overview/celdoxome-pegylated-liposomal-epar-medicine-overview_lt.pdf)

magyar (HU) (176.45 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/hu/documents/overview/celdoxome-pegylated-liposomal-epar-medicine-overview_hu.pdf)

Malti (MT) (179.54 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/mt/documents/overview/celdoxome-pegylated-liposomal-epar-medicine-overview_mt.pdf)

Nederlands (NL) (154.28 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/nl/documents/overview/celdoxome-pegylated-liposomal-epar-medicine-overview_nl.pdf)

polski (PL) (179.58 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/pl/documents/overview/celdoxome-pegylated-liposomal-epar-medicine-overview_pl.pdf)

português (PT) (154.96 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/pt/documents/overview/celdoxome-pegylated-liposomal-epar-medicine-overview_pt.pdf)

română (RO) (174.31 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/ro/documents/overview/celdoxome-pegylated-liposomal-epar-medicine-overview_ro.pdf)

slovenčina (SK) (176.86 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/sk/documents/overview/celdoxome-pegylated-liposomal-epar-medicine-overview_sk.pdf)

slovenščina (SL) (175.1 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/sl/documents/overview/celdoxome-pegylated-liposomal-epar-medicine-overview_sl.pdf)

Suomi (FI) (151.73 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/fi/documents/overview/celdoxome-pegylated-liposomal-epar-medicine-overview_fi.pdf)

svenska (SV) (152.18 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/sv/documents/overview/celdoxome-pegylated-liposomal-epar-medicine-overview_sv.pdf)

Celdoxome pegylated liposomal : EPAR - Risk management plan summary

English (EN) (117.78 KB - PDF)

**First published:** 31/01/2023

**Last updated:** 27/11/2025

[View](/en/documents/rmp-summary/celdoxome-pegylated-liposomal-epar-risk-management-plan-summary_en.pdf)

## Product information

Celdoxome pegylated liposomal : EPAR - Product Information

English (EN) (278.79 KB - PDF)

**First published:** 31/01/2023

**Last updated:** 27/11/2025

[View](/en/documents/product-information/celdoxome-pegylated-liposomal-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-274)

български (BG) (494.88 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/bg/documents/product-information/celdoxome-pegylated-liposomal-epar-product-information_bg.pdf)

español (ES) (317.27 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/es/documents/product-information/celdoxome-pegylated-liposomal-epar-product-information_es.pdf)

čeština (CS) (489.75 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/cs/documents/product-information/celdoxome-pegylated-liposomal-epar-product-information_cs.pdf)

dansk (DA) (325.29 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/da/documents/product-information/celdoxome-pegylated-liposomal-epar-product-information_da.pdf)

Deutsch (DE) (340.2 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/de/documents/product-information/celdoxome-pegylated-liposomal-epar-product-information_de.pdf)

eesti keel (ET) (341.28 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/et/documents/product-information/celdoxome-pegylated-liposomal-epar-product-information_et.pdf)

ελληνικά (EL) (534.94 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/el/documents/product-information/celdoxome-pegylated-liposomal-epar-product-information_el.pdf)

français (FR) (336.19 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/fr/documents/product-information/celdoxome-pegylated-liposomal-epar-product-information_fr.pdf)

hrvatski (HR) (429.2 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/hr/documents/product-information/celdoxome-pegylated-liposomal-epar-product-information_hr.pdf)

íslenska (IS) (304.58 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/is/documents/product-information/celdoxome-pegylated-liposomal-epar-product-information_is.pdf)

italiano (IT) (354.23 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/it/documents/product-information/celdoxome-pegylated-liposomal-epar-product-information_it.pdf)

latviešu valoda (LV) (434.99 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/lv/documents/product-information/celdoxome-pegylated-liposomal-epar-product-information_lv.pdf)

lietuvių kalba (LT) (400.21 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/lt/documents/product-information/celdoxome-pegylated-liposomal-epar-product-information_lt.pdf)

magyar (HU) (461.69 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/hu/documents/product-information/celdoxome-pegylated-liposomal-epar-product-information_hu.pdf)

Malti (MT) (474.82 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/mt/documents/product-information/celdoxome-pegylated-liposomal-epar-product-information_mt.pdf)

Nederlands (NL) (318.79 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/nl/documents/product-information/celdoxome-pegylated-liposomal-epar-product-information_nl.pdf)

norsk (NO) (306.29 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/no/documents/product-information/celdoxome-pegylated-liposomal-epar-product-information_no.pdf)

polski (PL) (451.13 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/pl/documents/product-information/celdoxome-pegylated-liposomal-epar-product-information_pl.pdf)

português (PT) (325.45 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/pt/documents/product-information/celdoxome-pegylated-liposomal-epar-product-information_pt.pdf)

română (RO) (463.24 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/ro/documents/product-information/celdoxome-pegylated-liposomal-epar-product-information_ro.pdf)

slovenčina (SK) (446.5 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/sk/documents/product-information/celdoxome-pegylated-liposomal-epar-product-information_sk.pdf)

slovenščina (SL) (419.4 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/sl/documents/product-information/celdoxome-pegylated-liposomal-epar-product-information_sl.pdf)

Suomi (FI) (322.91 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/fi/documents/product-information/celdoxome-pegylated-liposomal-epar-product-information_fi.pdf)

svenska (SV) (296.75 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/sv/documents/product-information/celdoxome-pegylated-liposomal-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** H/C/005330/T/0004 21/03/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Celdoxome pegylated liposomal : EPAR - All authorised presentations

English (EN) (82.01 KB - PDF)

**First published:** 31/01/2023

**Last updated:** 27/11/2025

[View](/en/documents/all-authorised-presentations/celdoxome-pegylated-liposomal-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-969)

български (BG) (103.91 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/bg/documents/all-authorised-presentations/celdoxome-pegylated-liposomal-epar-all-authorised-presentations_bg.pdf)

español (ES) (56.5 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/es/documents/all-authorised-presentations/celdoxome-pegylated-liposomal-epar-all-authorised-presentations_es.pdf)

čeština (CS) (74.13 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/cs/documents/all-authorised-presentations/celdoxome-pegylated-liposomal-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (58.98 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/da/documents/all-authorised-presentations/celdoxome-pegylated-liposomal-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (58.73 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/de/documents/all-authorised-presentations/celdoxome-pegylated-liposomal-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (55.93 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/et/documents/all-authorised-presentations/celdoxome-pegylated-liposomal-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (77.29 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/el/documents/all-authorised-presentations/celdoxome-pegylated-liposomal-epar-all-authorised-presentations_el.pdf)

français (FR) (56.48 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/fr/documents/all-authorised-presentations/celdoxome-pegylated-liposomal-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (127.7 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/hr/documents/all-authorised-presentations/celdoxome-pegylated-liposomal-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (58.37 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/is/documents/all-authorised-presentations/celdoxome-pegylated-liposomal-epar-all-authorised-presentations_is.pdf)

italiano (IT) (55.88 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/it/documents/all-authorised-presentations/celdoxome-pegylated-liposomal-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (74.05 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/lv/documents/all-authorised-presentations/celdoxome-pegylated-liposomal-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (75.91 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/lt/documents/all-authorised-presentations/celdoxome-pegylated-liposomal-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (66.38 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/hu/documents/all-authorised-presentations/celdoxome-pegylated-liposomal-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (77.65 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/mt/documents/all-authorised-presentations/celdoxome-pegylated-liposomal-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (56.19 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/nl/documents/all-authorised-presentations/celdoxome-pegylated-liposomal-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (58.19 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/no/documents/all-authorised-presentations/celdoxome-pegylated-liposomal-epar-all-authorised-presentations_no.pdf)

polski (PL) (77.85 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/pl/documents/all-authorised-presentations/celdoxome-pegylated-liposomal-epar-all-authorised-presentations_pl.pdf)

português (PT) (57.35 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/pt/documents/all-authorised-presentations/celdoxome-pegylated-liposomal-epar-all-authorised-presentations_pt.pdf)

română (RO) (73.81 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/ro/documents/all-authorised-presentations/celdoxome-pegylated-liposomal-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (75.8 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/sk/documents/all-authorised-presentations/celdoxome-pegylated-liposomal-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (65 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/sl/documents/all-authorised-presentations/celdoxome-pegylated-liposomal-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (55.69 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/fi/documents/all-authorised-presentations/celdoxome-pegylated-liposomal-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (56.91 KB - PDF)

**First published:**

31/01/2023

**Last updated:**

27/11/2025

[View](/sv/documents/all-authorised-presentations/celdoxome-pegylated-liposomal-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Celdoxome pegylated liposomal Active substance doxorubicin hydrochloride International non-proprietary name (INN) or common name doxorubicin hydrochloride Therapeutic area (MeSH)

- Breast Neoplasms
- Ovarian Neoplasms
- Multiple Myeloma
- Sarcoma, Kaposi

Anatomical therapeutic chemical (ATC) code L01DB01

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Celdoxome pegylated liposomal is indicated in adults:

- as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk.
- or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen.
- in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.
- for treatment of AIDS-related Kaposi's sarcoma (KS) in patients with low CD4 counts (&lt; 200 CD4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease.

Celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

## Authorisation details

EMA product number EMEA/H/C/005330 Marketing authorisation holder

Baxter Holding B.V.

Kobaltweg 49 3542 CE Utrecht Netherlands

Opinion adopted 21/07/2022 Marketing authorisation issued 15/09/2022 Lapse of marketing authorisation 22/09/2025 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Celdoxome pegylated liposomal : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (158.51 KB - PDF)

**First published:** 05/09/2023

**Last updated:** 27/11/2025

[View](/en/documents/procedural-steps-after/celdoxome-pegylated-liposomal-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Celdoxome pegylated liposomal-H-C-PSUSA-00001172-202211 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/400469/2023

English (EN) (115.56 KB - PDF)

**First published:** 05/09/2023

**Last updated:** 27/11/2025

[View](/en/documents/scientific-conclusion/celdoxome-pegylated-liposomal-h-c-psusa-00001172-202211-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Celdoxome pegylated liposomal : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/685994/2022

English (EN) (1.69 MB - PDF)

**First published:** 31/01/2023

**Last updated:** 27/11/2025

[View](/en/documents/assessment-report/celdoxome-pegylated-liposomal-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Celdoxome pegylated liposomal

Adopted

Reference Number: EMA/CHMP/655859/2022

English (EN) (135.5 KB - PDF)

**First published:** 22/07/2022

**Last updated:** 27/11/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-celdoxome-pegylated-liposomal_en.pdf)

#### News on Celdoxome pegylated liposomal

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-july-2022) 22/07/2022

**This page was last updated on** 27/11/2025

## Share this page

[Back to top](#main-content)